Study guide

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy

Key Takeaways Explain This Topic AI

Naltrexone is a competitive mu-opioid receptor antagonist that blocks endogenous beta-endorphin from disinhibiting dopaminergic projection neurons in the ventral tegmental area, thereby attenuating alcohol-induced reward, euphoria, and craving.

Oral naltrexone is prescribed at 50 mg daily (typically initiated with a 25 mg test dose taken with food to minimize nausea); targeted dosing (the Sinclair Method) prescribes 50 mg taken 1 to 2 hours prior to anticipated alcohol consumption to promote pharmacological extinction.

Extended-release injectable naltrexone (Vivitrol, 380 mg IM every 4 weeks in alternating gluteal muscles) circumvents daily adherence failures; deep intramuscular administration using custom 1.5-inch or 2.0-inch needles is mandatory to prevent severe subcutaneous necrosis.

Naltrexone is absolutely contraindicated in patients with current opioid use, physiological opioid dependence, or acute opioid withdrawal; patients must be opioid-free for 7 to 10 days for short-acting opioids and at least 14 days for buprenorphine or methadone, verified by objective drug testing and an optional naloxone challenge.

Perioperative pain planning requires discontinuing oral naltrexone 72 hours prior to elective surgery and scheduling surgery 4 weeks after the last Vivitrol injection; emergency analgesia requires multimodal non-opioid strategies or high-potency opioids in an intensive care setting with continuous monitoring.

Last updated: September 2026

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy

Quick Answer: Naltrexone is a competitive μ \mu μ -opioid receptor (MOR) antagonist that disrupts alcohol's positive reinforcing effects by preventing endogenous β \beta β -endorphin from disinhibiting dopamine release in the nucleus accumbens . It is available as an oral tablet (50 mg/day) and an extended-release intramuscular suspension (Vivitrol 380 mg every 4 weeks) . Naltrexone's primary clinical efficacy lies in reducing heavy drinking days and blunting alcohol cravings. It is strictly contraindicated in patients taking opioids or with physiological opioid dependence, requiring a 7- to 10-day opioid-free interval (14 days for methadone or buprenorphine) to avoid precipitating acute, severe opioid withdrawal. Perioperatively, oral naltrexone must be stopped 72 hours prior to elective surgery, while Vivitrol requires a 4-week window .

1. Neurobiological Mechanism of Action in AUD

Alcohol (ethanol) consumption induces complex central neurochemical cascades. Although ethanol does not bind directly to an "alcohol receptor," it triggers the rapid synthesis and exocytosis of endogenous opioid peptides—most notably β \beta β -endorphin —from the arcuate nucleus of the hypothalamus and the ventral tegmental area (VTA) . [Ethanol Ingestion]

  • │
  • ▼
  • [Release of Endogenous β-Endorphin in VTA]
  • │
  • ▼
  • [Activation of μ-Opioid Receptors (MOR) on Local GABAergic Interneurons]
  • │
  • ▼ (Inhibition of GABA Release — "The Brake is Released")
  • [Disinhibition of Dopaminergic Projection Neurons]
  • │
  • ▼
  • [Phasic Surge of Dopamine into Nucleus Accumbens (NAc) Shell]
  • │
  • ▼
  • [Subjective Euphoria, Reward Reinforcement & Alcohol Craving]
  • Mu-Opioid Receptor Antagonism & Dopaminergic Blunting

Under drug-free physiological conditions, tonic GABAergic interneurons in the VTA act as a continuous "brake," restraining dopamine projection neurons from firing uncontrollably. When ethanol induces β \beta β -endorphin release, β \beta β -endorphin binds to μ \mu μ -opioid receptors on these inhibitory GABA interneurons. MOR activation hyperpolarizes and silences the interneurons, lifting the brake and causing disinhibition of dopaminergic neurons. The resulting dopaminergic efflux into the nucleus accumbens (NAc) shell encodes the hedonic "buzz," reinforces drug-seeking behavior, and drives incentive salience.

Naltrexone and its major active hepatic metabolite, 6 β 6\beta 6 β -naltrexol , are high-affinity, competitive antagonists at μ \mu μ - and κ \kappa κ -opioid receptors (and to a lesser degree, δ \delta δ -opioid receptors):

Receptor Displacement: Naltrexone competitively occupies the orthosteric binding pocket of μ \mu μ -opioid receptors on VTA GABAergic interneurons, blocking β \beta β -endorphin from binding.

Restoration of Inhibitory Tone: Because β \beta β -endorphin cannot bind, GABA interneurons remain active and continue releasing GABA onto adjacent dopamine neurons.

Reward Blunting: Even if the individual ingests alcohol, the anticipated phasic dopamine surge in the nucleus accumbens is blunted or prevented. The patient perceives alcohol as significantly less euphoric, less rewarding, and less satisfying.

Extinction of Conditioned Reinforcement: Over repeated drinking episodes under naltrexone blockade, the behavioral link between alcohol consumption and neurochemical reward is weakened, leading to pharmacological extinction of craving and a dramatic decrease in heavy drinking days.

2. Prescribing Protocols & Formulations

Advanced practice registered nurses (APRNs) must match the naltrexone formulation to patient preferences, adherence history, financial coverage, and clinical presentation.

Oral Naltrexone Protocol

Oral naltrexone is FDA-approved as an adjunct to psychosocial therapy for the treatment of alcohol dependence.

Standard Maintenance Dose: 50 mg orally once daily .

Initiation Strategy: Gastrointestinal intolerance (nausea, abdominal cramps, anorexia) and headache are the most common reasons for early discontinuation. To optimize tolerability:

Initiate at 25 mg daily (half of a 50 mg tablet) taken with or immediately after a substantial meal for the first 2 to 3 days.

If well tolerated, increase to the full therapeutic dose of 50 mg daily .

Some clinical trials and specialized addiction settings utilize higher doses (100–150 mg/day) in patients with elevated body mass index (BMI) or incomplete craving suppression, though adverse effects increase proportionally.

Duration of Therapy: Guidelines recommend maintaining therapy for a minimum of 3 to 6 months . Prolonged therapy (12 months or longer) is common and safe for patients who demonstrate sustained clinical stability.

Targeted Dosing (The Sinclair Method)

While daily administration is the FDA-approved standard in the United States, targeted dosing (popularized as the Sinclair Method ) is an evidence-based alternative protocol widely utilized in harm-reduction paradigms and European clinical practice:

Protocol: The patient does not take naltrexone on abstinent days. Instead, the patient takes 50 mg orally strictly 1 to 2 hours prior to the first drink of an anticipated drinking episode.

Underlying Neurobiology: Pharmacological extinction requires the concurrent presence of the behavioral cue, ethanol consumption, and opioid receptor blockade. By taking naltrexone only prior to drinking, each drinking session systematically uncouples the conditioned stimulus from the neurochemical reward, gradually extinguishing the psychological compulsion to drink.

Candidate Profile: Ideal for patients whose treatment goal is moderation or reduction of heavy drinking rather than immediate absolute abstinence, or patients who refuse daily pharmacotherapy.

Extended-Release Injectable Naltrexone (Vivitrol)

Oral medication adherence in substance use disorders averages below 50%. Extended-release injectable naltrexone (Vivitrol) provides therapeutic plasma concentrations of naltrexone ( > 1 – 2 ng/mL >1\text{–}2\text{ ng/mL} > 1 – 2 ng/mL ) for a full 28 days, completely eliminating daily adherence friction.

Dosing & Schedule: 380 mg administered once every 4 weeks (every 28 days) .

Administration Technique (CRITICAL):

Administered exclusively by a trained healthcare professional via deep intramuscular (IM) gluteal injection .

Strictly alternate buttocks each month.

Never inject subcutaneously or intravenously. Subcutaneous deposition causes severe local tissue damage, sterile abscesses, persistent nodules, fat necrosis, and extensive skin sloughing requiring surgical debridement.

Needle Selection: The manufacturer-supplied needle must be utilized. Use the 1.5-inch needle for normal-weight individuals and the 2.0-inch needle for patients with significant adipose tissue / obesity to ensure deep intramuscular penetration.

Allow the medication carton to reach room temperature (approximately 45 minutes) prior to reconstituting with the supplied diluent, and inject immediately upon smooth suspension.

Clinical Efficacy Profile: Naltrexone vs. Acamprosate

Large-scale clinical trials (including the landmark COMBINE Study ) demonstrate distinct efficacy profiles across MAUDs:

Heavy Drinking Days: Naltrexone demonstrates superior efficacy in reducing heavy drinking days ( > 4 >4 > 4 drinks/day for women, > 5 >5 > 5 drinks/day for men), decreasing the quantity of alcohol consumed per drinking occasion, and preventing a single "slip" from escalating into a full relapse.

Abstinence Maintenance: Acamprosate shows greater relative efficacy in supporting continuous, complete abstinence in patients who are already detoxified and sober.

3. Contraindications, Precautions & Laboratory Monitoring

Clinical Parameter Clinical Finding / Threshold Management / Action

Current Opioid Use Active full or partial opioid agonist therapy Absolute Contraindication ; precipitates severe withdrawal

Opioid Washout (Short-Acting) Hydrocodone, oxycodone, morphine, heroin Must be verified opioid-free for 7 to 10 days

Opioid Washout (Long-Acting) Methadone, buprenorphine Must be verified opioid-free for at least 14 days

Hepatic Function Acute hepatitis, hepatic failure, decompensated cirrhosis Absolute Contraindication ; monitor baseline AST, ALT, bilirubin

Transaminase Elevations Baseline AST or ALT > 3 – 5 × >3\text{–}5\times > 3 – 5 × Upper Limit of Normal (ULN) Withhold initiation; evaluate etiology; recheck in 2–4 weeks

Injection Site Reactions Induration, pain, erythema, swelling, necrosis Monitor closely; surgical consultation if skin necrosis occurs

Opioid-Free Verification & The Naloxone Challenge

Administering naltrexone to an individual with physiological opioid dependence causes immediate displacement of opioids from receptor sites, triggering severe, refractory, precipitated opioid withdrawal characterized by violent vomiting, explosive diarrhea, hypertension, tachycardia, extreme dysphoria, and hemodynamic collapse.

History & Toxicological Screening: Obtain a thorough substance use history and confirm a negative comprehensive urine drug screen (including synthetic opioids such as fentanyl, buprenorphine, and methadone).

Naloxone Challenge Test: When the clinical history is ambiguous or recent undisclosed opioid use is suspected:

Administer 0.4 mg IV naloxone (or 0.8 mg subcutaneous) and observe the patient for 20 to 30 minutes .

Monitor for objective signs of opioid withdrawal (piloerection, pupillary dilation, rhinorrhea, diaphoresis, yawning, tremors, tachycardia, abdominal cramping).

If withdrawal signs emerge, do not administer naltrexone . Re-evaluate in 24 to 48 hours.

If the naloxone challenge is negative, the patient can safely proceed to naltrexone induction.

Hepatic Considerations & Monitoring Protocols

Historical Context: In the 1980s, the FDA placed a boxed warning on oral naltrexone due to observed hepatocellular injury when administered at supratherapeutic doses ( 300 mg/day 300\text{ mg/day} 300 mg/day ) in clinical trials for obesity. Subsequent clinical trials in AUD using therapeutic doses ( 50 mg/day 50\text{ mg/day} 50 mg/day or Vivitrol 380 mg/month 380\text{ mg/month} 380 mg/month ) demonstrated an exceptionally low incidence of hepatotoxicity. In 2013, the FDA officially removed the black box warning for hepatotoxicity from oral naltrexone.

Contemporary APRN Guidelines:

Mild, stable elevations in transaminases ( A S T / A L T < 3 × ULN AST/ALT < 3\times\text{ ULN} A ST / A L T < 3 × ULN ) secondary to chronic alcohol-induced steatosis are common and do not preclude naltrexone initiation; in fact, transaminases frequently normalize as alcohol consumption declines.

Naltrexone is contraindicated in acute viral or alcoholic hepatitis, acute hepatic failure, and decompensated cirrhosis (Child-Pugh Class C with ascites, jaundice, or encephalopathy).

Obtain baseline liver function tests (LFTs). Repeat LFTs at 1 month, 3 months, 6 months, and annually thereafter. Discontinue naltrexone if AST or ALT exceeds 3 to 5 × ULN 3\text{ to }5\times\text{ ULN} 3 to 5 × ULN or if clinical jaundice/symptoms of hepatitis appear.

4. Pain Management Protocols & Patient Safety

Naltrexone creates profound clinical challenges when acute surgical or traumatic pain management is required.

Elective Surgical Planning

For patients undergoing planned operative procedures where postoperative opioid analgesia may be required:

Oral Naltrexone: Discontinue medication at least 72 hours prior to the scheduled surgery to allow complete clearance of naltrexone and its active 6 β 6\beta 6 β -naltrexol metabolite.

Injectable Vivitrol: Schedule elective surgery for the nadir of the dosing cycle , ideally 4 weeks (28 to 32 days) following the last injection .

Postoperative Resumption: Naltrexone may be restarted once postoperative healing is adequate, opioid analgesics have been discontinued, and an opioid-free window of 7 to 10 days has elapsed. [Elective Surgery Timeline - Oral Naltrexone]

  • 72 Hours: Discontinue Oral Naltrexone 50 mg
  • Day 0: Surgery (Standard Anesthesia / Opioid Regimens)
  • Post-Op Days 1-7: Taper and Discontinue All Opioid Analgesics
  • Post-Op Days 8-17: 7-10 Day Opioid-Free Washout Window (Confirm Neg UDS)
  • Day 18+: Resume Oral Naltrexone 50 mg Daily
  • Emergency & Trauma Analgesia Protocols

In the event of emergent trauma or acute surgical illness in a patient currently blocked by naltrexone, standard opioid analgesia will fail due to competitive antagonism:

Prioritize Non-Opioid Multimodal Analgesia:

Regional & Neuraxial Anesthesia: Peripheral nerve blocks, transversus abdominis plane (TAP) blocks, and epidural/spinal local anesthetics (e.g., ropivacaine, bupivacaine).

NMDA Receptor Antagonists: Subanesthetic intravenous ketamine infusions ( 0.1 – 0.3 mg/kg/hr 0.1\text{–}0.3\text{ mg/kg/hr} 0.1 – 0.3 mg/kg/hr ) provide powerful central analgesia via non-opioid mechanisms.

Alpha-2 Adrenergic Agonists: Intravenous dexmedetomidine or oral clonidine .

Parenteral Non-Opioids: Intravenous acetaminophen and IV ketorolac (NSAID).

Overcoming Receptor Blockade with High-Potency Opioids (CRITICAL CAUTION):

If opioid analgesia is strictly necessary, high-affinity synthetic opioids (such as fentanyl or sufentanil ) may be titrated to outcompete naltrexone at the receptor level.

MANDATORY SAFETY SETTING: This must be performed exclusively in an intensive care unit (ICU) or operating room setting with continuous electrocardiographic, end-tidal C O 2 CO_2 C O 2 ​ (capnography), and pulse oximetry monitoring, with immediate availability of advanced airway equipment.

Delayed Fatal Apnea Risk: The dose of fentanyl required to overcome naltrexone blockade is markedly higher than normal therapeutic doses. As the competitive equilibrium shifts or naltrexone dissociates from the receptor, massive residual concentrations of circulating opioids can suddenly trigger catastrophic, fatal respiratory arrest.

Patient Education: Opioid Resensitization & Overdose Risk

Chronic blockade of μ \mu μ -opioid receptors by naltrexone causes compensatory upregulation and hypersensitization of opioid receptors throughout the central nervous system. When naltrexone is discontinued, or towards the end of a 4-week Vivitrol dosing interval:

The patient's baseline physiological tolerance to opioids is completely lost .

Opioid receptors exhibit heightened sensitivity to both endogenous and exogenous opioids.

If the patient relapses to opioids or attempts to take high doses of opioids to "override" the blockade, doses that were previously well-tolerated will cause rapid, fatal respiratory depression .

Mandatory Nursing Actions: Educate every patient and family member regarding this vulnerability, prescribe a take-home intranasal naloxone (Narcan) kit, and instruct the patient to carry a medical alert wallet card or wear a medical alert bracelet indicating they are on extended-release naltrexone therapy.